REG - Trellus Health PLC - Directorate Change

Trellus HealthAnnouncement

28/02/2024 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240228:nRSb8145Ea&default-theme=true

RNS Number : 8145E  Trellus Health PLC  28 February 2024

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Directorate Change

 

LONDON, U.K. AND NEW YORK, U.S. (28 February 2024). Trellus Health plc (AIM:
TRLS) which is providing scientifically validated, innovative value-based
personalized solutions and services for chronic health conditions at their
intersection with mental health, prioritizing improved outcomes while managing
costs of care.

 

The Company announces that Non-Executive Director, Christopher Mills, will
step down from the Board with immediate effect.

 

Dr. Daniel Mahony, Non-Executive Chairman of Trellus Health, said: "On behalf
of the Board of Directors of Trellus Health, I would like to thank Christopher
for his significant contributions to the Company from the beginning,
especially as we moved towards commercial scale. As we continue to progress
our commercialisation strategy, highlighted by our recent agreement with a
large US health plan, we will look to appoint a new director in due course
with experience of the US managed care industry."

 

For further information please contact:

 

 Trellus Health plc                                                           https://trellushealth.com/ (https://trellushealth.com/)
 Dr. Marla Dubinsky, CEO and Co-Founder                                       Via Walbrook PR
 Dr. Daniel Mahony, Chairman
 Singer Capital Markets (Nominated Adviser and Broker)                        Tel: +44 (0)20 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR                                  Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                                              (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen / Phillip Marriage  Mob: +44 (0)7980 541 893 / (0)7502 558 258/ (0)7867 984 082

 

This announcement contains inside information for the purposes of the retained
UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (AIM: TRLS) is the first clinically-proven digital health
company targeting the intersection of chronic illness and mental health.
Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate™, a whole-person technology-enhanced experience that
empowers individuals to master their health and results in relieving disease
burden, building self-management skills and promoting positive health
behaviours that improve outcomes and enables thriving in the face of a chronic
condition.

 

The Company's proven whole person approach recognizes the interconnectedness
of various aspects of a person's life and aims to address the whole spectrum
of factors that influence behaviour. By looking at all aspects of an
individual, the Company not only treats symptoms but promotes comprehensive
well-being and human flourishing. Trellus Health addresses behavior change
with a combination of technology, interventions, education, and support
mechanisms designed to empower individuals to take an active role in managing
and mastering their health and sustain positive lifestyle modifications and
resilient health-related behaviours. By bringing these components together,
Trellus Elevate™ promotes positive change in individual behaviours and
enhancing provider quality metrics in a way that aligns with value-based care.
Our approach enables better health outcomes in a member-centric, personalized
and holistic comprehensive solution.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both experts at treating and healing both the physical
and emotional impacts of IBD and IBS and have been innovators for whole person
healthcare for a combined 50 years.

 

The Company is initially focusing on chronic costly GI conditions that have
high mental health burden, like inflammatory bowel disease ("IBD") which
includes the chronic incurable conditions of Crohn's Disease and ulcerative
colitis and Irritable Bowel Syndrome ("IBS"). Given the common emotional and
mental health struggles often experienced by individuals suffering from a
variety of chronic conditions, Trellus Health considers its approach to be
agnostic, having potential utility and demand across many conditions.

 

The Trellus Elevate™ program incorporates the GRITT™ methodology and
learnings on resilience from clinical research and practice conducted at the
Mount Sinai IBD Center for more than seven years. This proprietary,
resilience-driven methodology has been scientifically validated to demonstrate
meaningful improvements in patient outcomes, 71% reduction in Emergency
Department (A&E) visits, and 94% reduction in unplanned hospitalisations,
which the directors of the Company believe indicates the potential for
significant cost savings for healthcare payers and health systems. Patients
with IBD managed with the proprietary resilience methodology also experienced
a 49% reduction in required opioid use and a 73% reduction in corticosteroid
use 12 months following starting the program which is a major indicator of
improved health outcomes(1.)

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information on Trellus Health, visit:
www.trellushealth.com (http://www.trellushealth.com)

 

(1) Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
(https://www.sciencedirect.com/science/article/pii/S1542356521012258) )

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABBGDDRUDDGSI